Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis

[at noodls] – SP-333 Advances to Multiple-Dosing Safety Study NEW YORK, Jan. 28, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders, announced today … more

View todays social media effects on SGYPW

View the latest stocks trending across Twitter. Click to view dashboard

See who Synergy is hiring next, click here to view